About SUMMIT THERAPEU/S (NASDAQ:SMMT)
Summit Therapeutics plc, a biopharmaceutical company, focuses on the discovery, development, and commercialization of novel medicines to treat genetic and infectious diseases in the United Kingdom and North America. It is conducting clinical programmes focused on the genetic disease Duchenne muscular dystrophy (DMD) and the infectious disease Clostridium difficile infection (CDI). The company's lead DMD product candidate is ezutromid, an orally administered small molecule, which is in Phase II clinical trial in patients with DMD; and lead CDI product candidate is ridinilazole, an orally administered small molecule antibiotic that has completed Phase II clinical trials for the treatment of CDI disease. It has strategic alliance with the University of Oxford to develop utrophin modulators. The company was formerly known as Summit Corporation plc and changed its name to Summit Therapeutics plc in February 2015. Summit Therapeutics plc was founded in 2003 and is based in Abingdon, the United Kingdom.
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Trailing P/E Ratio-16.65
Forward P/E Ratio-5.34
Sales & Book Value
Annual Sales$36.07 million
Price / Sales4.63
Price / CashN/A
Book Value$0.93 per share
Price / Book12.98
EPS (Most Recent Fiscal Year)($0.75)
Return on Equity-105.24%
Return on Assets-17.79%
SUMMIT THERAPEU/S (NASDAQ:SMMT) Frequently Asked Questions
What is SUMMIT THERAPEU/S's stock symbol?
SUMMIT THERAPEU/S trades on the NASDAQ under the ticker symbol "SMMT."
How were SUMMIT THERAPEU/S's earnings last quarter?
SUMMIT THERAPEU/S (NASDAQ:SMMT) released its earnings results on Tuesday, June, 5th. The company reported ($0.55) earnings per share for the quarter, beating the Thomson Reuters' consensus estimate of ($0.76) by $0.21. The company had revenue of $5.33 million for the quarter, compared to the consensus estimate of $6.48 million. SUMMIT THERAPEU/S had a negative return on equity of 105.24% and a negative net margin of 33.36%. View SUMMIT THERAPEU/S's Earnings History.
When is SUMMIT THERAPEU/S's next earnings date?
What price target have analysts set for SMMT?
7 Wall Street analysts have issued 1 year price objectives for SUMMIT THERAPEU/S's shares. Their predictions range from $20.00 to $33.00. On average, they expect SUMMIT THERAPEU/S's share price to reach $27.00 in the next year. View Analyst Ratings for SUMMIT THERAPEU/S.
Who are some of SUMMIT THERAPEU/S's key competitors?
Some companies that are related to SUMMIT THERAPEU/S include GlycoMimetics (GLYC), Dicerna Pharmaceuticals (DRNA), Evolus (EOLS), Viking Therapeutics (VKTX), CannTrust (CNTTF), Progenics Pharmaceuticals (PGNX), Kura Oncology (KURA), Aduro BioTech (ADRO), Akebia Therapeutics (AKBA), Aclaris Therapeutics (ACRS), ChemoCentryx (CCXI), ZIOPHARM Oncology (ZIOP), Lannett (LCI), Keryx Biopharmaceuticals (KERX) and Beyondspring (BYSI).
Who are SUMMIT THERAPEU/S's key executives?
SUMMIT THERAPEU/S's management team includes the folowing people:
- Mr. Glyn O. Edwards MBE, Chief Exec. Officer and Exec. Director (Age 62)
- Mr. Erik Ostrowski, Chief Financial Officer (Age 45)
- Prof. Kay Davies FRS CBE, Co-Founder, Chairman of Scientific Advisory Board and Scientific Advisor (Age 68)
- Prof. David Roblin BSc, MBBS, FRCP, MFPM, Chief Operating Officer, Chief Medical Officer and Pres of R&D (Age 51)
- Ms. Michelle Avery, Director of Investor Relations
When did SUMMIT THERAPEU/S IPO?
(SMMT) raised $40 million in an initial public offering on Thursday, March 5th 2015. The company issued 3,500,000 shares at $11.54 per share. JMP Securities and Oppenheimer & Co. served as the underwriters for the IPO and Needham was co-manager.
Has SUMMIT THERAPEU/S been receiving favorable news coverage?
Headlines about SMMT stock have been trending positive recently, Accern Sentiment reports. Accern identifies negative and positive media coverage by analyzing more than twenty million news and blog sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores nearest to one being the most favorable. SUMMIT THERAPEU/S earned a news sentiment score of 0.34 on Accern's scale. They also gave news headlines about the company an impact score of 43.35 out of 100, indicating that recent media coverage is somewhat unlikely to have an effect on the company's share price in the next several days.
Who are SUMMIT THERAPEU/S's major shareholders?
SUMMIT THERAPEU/S's stock is owned by many different of institutional and retail investors. Top institutional shareholders include Point72 Asset Management L.P. (5.42%), Millennium Management LLC (0.17%) and Royal Bank of Canada (0.09%). View Institutional Ownership Trends for SUMMIT THERAPEU/S.
Which major investors are selling SUMMIT THERAPEU/S stock?
Which major investors are buying SUMMIT THERAPEU/S stock?
How do I buy shares of SUMMIT THERAPEU/S?
Shares of SMMT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is SUMMIT THERAPEU/S's stock price today?
One share of SMMT stock can currently be purchased for approximately $12.07.
How big of a company is SUMMIT THERAPEU/S?
SUMMIT THERAPEU/S has a market capitalization of $173.88 million and generates $36.07 million in revenue each year. The company earns $-9,280,000.00 in net income (profit) each year or ($0.75) on an earnings per share basis. SUMMIT THERAPEU/S employs 40 workers across the globe.
How can I contact SUMMIT THERAPEU/S?
SUMMIT THERAPEU/S's mailing address is 136a Eastern Avenue Milton Park, Abingdon X0, OX14 4RY. The company can be reached via phone at 44-12-3544-3939 or via email at [email protected]
MarketBeat Community Rating for SUMMIT THERAPEU/S (SMMT)MarketBeat's community ratings are surveys of what our community members think about SUMMIT THERAPEU/S and other stocks. Vote "Outperform" if you believe SMMT will outperform the S&P 500 over the long term. Vote "Underperform" if you believe SMMT will underperform the S&P 500 over the long term. You may vote once every thirty days.